Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

Lancet

Volumn 357, Issue 9255, 2001, Pages 525-526

  MacKie, Rona M ^a   Stewart, Barry ^b   Brown, S Moira ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ARTICLE; CELL DEATH; CLINICAL ARTICLE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0035901089     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04048-4     Document Type: Article

References (5)

1. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence
2. Cell type and cell state determine differentiated in vitro growth of non-neurovirulant ICP34.5-negative herpes simplex virus
3. A mutant herpes simplex virus replicates in brain tumours but not in neurons derived from a human embryonal carcinoma cell line
4. Treatment of experimental subcutaneous human melanoma with a replication restricted herpes simplex virus mutant
5. Toxicity evaluation of replication competent herpes simplex virus ICP34.5 null mutant 1716 in patients with recurrent glioma